Welcome to our dedicated page for Akari Therapeutics Plc news (Ticker: AKTX), a resource for investors and traders seeking the latest updates and insights on Akari Therapeutics Plc stock.
Akari Therapeutics Plc (AKTX) is a clinical-stage biopharmaceutical company advancing innovative treatments for rare autoimmune and inflammatory diseases. This page provides investors and industry observers with timely updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access comprehensive coverage of AKTX’s progress, including press releases on trial results, FDA designations, and partnership announcements. Our curated news collection focuses on developments related to coversin, nomacopan, and other pipeline candidates targeting complement-mediated disorders.
Key updates include progress in treating conditions like HSCT-TMA and Geographic Atrophy, manufacturing partnerships, and scientific presentations. All content is verified from primary sources to ensure accuracy for investment research and market analysis.
Bookmark this page for centralized access to AKTX’s latest developments in complement system therapeutics. Check regularly for objective updates on clinical advancements and corporate announcements relevant to biopharmaceutical investors.
Akari Therapeutics (Nasdaq: AKTX) announced its SITC 40 abstract and presentations on November 7 and 9, 2025 describing preclinical immune mechanism data for its novel ADC payload PH1.
The company reports that a Trastuzumab–PH1 ADC produced higher rates of complete colon-tumor regressions versus a comparator microtubule-inhibitor ADC when combined with an anti‑PD‑1 checkpoint inhibitor. The PH1 combination is attributed to neoantigen-driven immune activation, antigen-presenting cell, B-cell and T-cell engagement, and expansion of tumor‑killing gamma‑delta T cells. Poster and oral presentation details and times are provided for the SITC Annual Meeting.
Akari Therapeutics (Nasdaq: AKTX) announced on October 30, 2025 the formation of a Scientific Advisory Board and the inaugural appointment of Dr. Sara A. Hurvitz, MD, FACP.
Dr. Hurvitz is described as an international oncology expert with extensive clinical trial leadership and specific experience in antibody drug conjugates (ADCs) and breast cancer therapies. She currently holds leadership roles at the University of Washington School of Medicine and Fred Hutchinson Cancer Center. The company noted its ADC pipeline includes AKTX-101 (Trop2 ADC with PH1 payload) and future programs such as AKTX-102.
Akari Therapeutics (Nasdaq: AKTX) launched a new CEO Corner platform on Oct 22, 2025 to deliver expanded perspective on press releases, corporate developments and pipeline progress.
The video platform features Abizer Gaslightwala, President and CEO, and allows interested parties to ask questions and submit topics for future videos. The CEO Corner is accessible on the company website.
Akari Therapeutics (Nasdaq: AKTX) announced a registered direct offering of 3,125,000 ADS at $0.80 per ADS, representing gross proceeds of approximately $2.5 million. In a concurrent private placement the company will issue unregistered Series E and Series F warrants, each to purchase up to 3,125,000 ADS at an exercise price of $0.98. Series E warrants: exercisable on shareholder approval and five-year term; Series F warrants: exercisable on shareholder approval and 30-month term. The offering is expected to close on or about October 16, 2025. Net proceeds are intended for working capital, general corporate purposes, and continued R&D focused on the novel ADC payload.
The ADSs are offered under an effective Form S-3 shelf registration (File No. 333-289056) declared effective July 31, 2025; the warrants and underlying ADSs are unregistered.
Akari Therapeutics (Nasdaq: AKTX) filed two provisional patent applications with the USPTO on Oct 9, 2025 to broaden intellectual property around its novel spliceosome‑modulating payload PH1. One filing claims PH1's immuno‑oncology mode of action via spliceosome modulation; the second claims combination therapies pairing PH1 ADCs with checkpoint inhibitors, citing preclinical synergy. These filings build on a late‑September provisional covering alternative splicing targeting and are intended to protect disclosures planned for an oral presentation at SITC on Nov 9, 2025. The release highlights AKTX‑101 (Trop2‑PH1 ADC) and future programs including AKTX‑102 as part of the expanding PH1 ADC pipeline.
Akari Therapeutics (Nasdaq: AKTX) announced an abstract accepted for an oral presentation at the 40th Annual SITC Meeting on Nov 5-9, 2025 in National Harbor, MD. The oral talk, titled "A Novel Splicing-Targeted ADC Payload Drives Immune Activation, Synergy with Checkpoint Inhibitors, and Enhanced Therapeutic Potential beyond Cytotoxicity," will be presented by Satyajit Mitra, Ph.D. on Sunday, Nov 9, 2025 at 11:05 AM ET in the Potomac Ballroom. A related poster will be presented on Friday, Nov 7, 2025 in Prince George ABC Exhibit Halls. For more details see sitcancer.org.
Akari Therapeutics (NASDAQ: AKTX) has announced promising preclinical data for its novel ADC spliceosome modulating payload, PH1, targeting hormone refractory prostate cancer. The data demonstrates PH1's ability to suppress AR-V7 receptor levels, which drives metastatic castration resistant prostate cancer (mCRPC) progression.
The research showed PH1's effectiveness in both hormone-refractory and hormone-sensitive prostate cancer models. In hormone-sensitive cases, PH1 showed additive effects when combined with existing treatments like Xtandi and Erleada. This suggests potential for developing first-line combination therapies and addressing the significant unmet need in ARPI-resistant cases, where current treatment options are limited.
Akari Therapeutics (Nasdaq: AKTX) has filed a provisional patent application with the USPTO for its novel antibody drug conjugate (ADC) platform utilizing the spliceosome payload PH1 for cancer treatment. The patent covers the platform's unique mechanism of modulating alternative splicing within cancer cells.
The technology targets cancer cells' ability to hijack alternative splicing (AS) processes, which affects tumor formation, growth, and metastasis. The PH1 payload demonstrates potential in disrupting cancer cell survival mechanisms across multiple types of cancers, including those resistant to current therapies.
The patent strengthens Akari's intellectual property portfolio and supports the development of their ADC programs, including AKTX-101 (Trop2 ADC with PH1 payload) and AKTX-102 (undisclosed target).
Akari Therapeutics (NASDAQ: AKTX), an oncology biotechnology company focused on payload antibody drug conjugates (ADCs), will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York.
CEO Abizer Gaslightwala will deliver a presentation and conduct one-on-one meetings with registered investors. The presentation will be available via video webcast starting September 5, 2025, at 7:00 AM ET for registered attendees and will remain accessible on the company's website for 90 days.
Akari Therapeutics (Nasdaq: AKTX), an oncology biotechnology company, will participate in the Virtual Investor Closing Bell Series on September 4, 2025 at 4:00 PM ET. During the event, CEO Abizer Gaslightwala will present a corporate overview focusing on the company's innovative payload platform for developing next-generation antibody drug conjugates (ADCs) in cancer treatment.
The event will feature a moderated discussion followed by a live Q&A session with investors. The presentation will be accessible through a live video webcast on the company's website, with a replay available for 90 days after the event.
FAQ
What is the current stock price of Akari Therapeutics Plc (AKTX)?
What is the market cap of Akari Therapeutics Plc (AKTX)?
